FUNDAMANT: An interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 10, Issue 1, 2018, Pages

  Novak, Petr ^a   Schmidt, Reinhold ^b   Kontsekova, Eva ^a   Kovacech, Branislav ^a   Smolek, Tomas ^a   Katina, Stanislav ^a   Fialova, Lubica ^a   Prcina, Michal ^a   Parrak, Vojtech ^a   Dal Bianco, Peter ^c   Brunner, Martin ^c   Staffen, Wolfgang ^d   Rainer, Michael ^e   Ondrus, Matej ^a   Ropele, Stefan ^b   Smisek, Miroslav ^a   Sivak, Roman ^a   Zilka, Norbert ^a   Winblad, Bengt ^f   Novak, Michal ^a  

^a Axon Neuroscience CRM Services SE ^*  (Cyprus)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Christian Doppler Klinik   (Austria)

^e DANUBE HOSPITAL   (Austria)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Active immunotherapy; Alzheimer's disease; Clinical trial; Immunotherapy; Neurofibrillary pathology; Tau; Vaccine

Indexed keywords

AADVAC1; ALZHEIMER DISEASE VACCINE; APOLIPOPROTEIN E4; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; TAU PROTEIN; UNCLASSIFIED DRUG; MAPT PROTEIN, HUMAN;

ACTIVE IMMUNOTHERAPY; ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BEHAVIOR DISORDER; BODY WEIGHT GAIN; BRAIN ATROPHY; BRAIN HEMORRHAGE; CATEGORY FLUENCY TEST; CLINICAL ARTICLE; COGNITION ASSESSMENT; CONTROLLED ORAL WORD ASSOCIATION TEST; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXECUTIVE FUNCTION TEST; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE ERYTHEMA; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; INTERVENTION STUDY; LYMPHOCYTE SUBPOPULATION; MALE; MENTAL DISEASE; MOUSE; MULTICENTER STUDY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; TAUOPATHY; TREATMENT REFUSAL; URINARY TRACT INFECTION; VOLUMETRY; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; ALZHEIMER VACCINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; TAU PROTEINS; TREATMENT OUTCOME;

EID: 85055460613     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-018-0436-1     Document Type: Article

References (51)

1. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7(3):137-52.
2. Nelson PT, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-81.
3. Schneider LS, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275(3):251-83.
4. Wimo A, et al. The economic impact of dementia in Europe in 2008 - cost estimates from the Eurocode project. Int J Geriatr Psychiatry. 2011;26(8):825-32.
5. Bachurin SO, Bovina EV, Ustyugov AA. Drugs in clinical trials for Alzheimer's disease: the major trends. Med Res Rev. 2017;37(5):1186-225.
6. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-59.
7. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430(7000):631-9.
8. Whitwell JL, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol. 2012;11(10):868-77.
9. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609-22.
10. Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2016;12(1):15-27.
11. Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):5-21.
12. Zilka N, Korenova M, Novak M. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies. Acta Neuropathol. 2009;118(1):71-86.
13. Cummings J, et al. Alzheimer's disease drug development pipeline: 2017. Alzheimers Dement (N Y). 2017;3(3):367-84.
14. Agadjanyan MG, Petrovsky N, Ghochikyan A. A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimers Dement. 2015;11(10):1246-59.
15. Pineda C, et al. Assessing the immunogenicity of biopharmaceuticals. BioDrugs. 2016;30(3):195-206.
16. Gilman S, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553-62.
17. Novak P, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017;16(2):123-34.
18. Vandenberghe R, et al. Active Aβ immunotherapy CAD106 in Alzheimer's disease: a phase 2b study. Alzheimers Dement (N Y). 2017;3(1):10-22.
19. Kontsekova E, et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther. 2014;6(4):44.
20. Kontsekova E, et al. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. Alzheimers Res Ther. 2014;6(4):45.
21. Sperling RA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.
22. Tariot PN, et al. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: a study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. Alzheimers Dement (N Y). 2018;4:150-60.
23. Yanamandra K, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2(3):278-88.
24. Bright J, et al. Human secreted tau increases amyloid-β production. Neurobiol Aging. 2015;36(2):693-709.
25. Theunis C, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013;8(8):e72301.
26. Collin L, et al. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain. 2014;137(Pt 10):2834-46.
27. Czerkowicz J, et al. Pan-tau antibody Biib076 exhibits promising safety and biomarker profile in cynomolgus monkey toxicity study [abstract P4-039]. Alzheimers Dement. 2018;13(7 Suppl):P1271.
28. Zilka N, et al. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett. 2006;580(15):3582-8.
29. Smith SM, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002;17(1):479-89.
30. Smith SM, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23(Suppl 1):S208-19.
31. Reuter M, et al. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage. 2012;61(4):1402-18.
32. Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration: a robust approach. Neuroimage. 2010;53(4):1181-96.
33. Zimova I, et al. Human truncated tau induces mature neurofibrillary pathology in a mouse model of human tauopathy. J Alzheimers Dis. 2016;54(2):831-43.
34. Arrighi HM, et al. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. J Neurol Neurosurg Psychiatry. 2016;87(1):106-12.
35. McKhann GM, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-9.
36. Barnes J, et al. A comparison of methods for the automated calculation of volumes and atrophy rates in the hippocampus. Neuroimage. 2008;40(4):1655-71.
37. Cash DM, et al. Assessing atrophy measurement techniques in dementia: results from the MIRIAD atrophy challenge. Neuroimage. 2015;123:149-64.
38. Grundke-Iqbal I, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83(13):4913-7.
39. Novak M, et al. Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. Proc Natl Acad Sci U S A. 1991;88(13):5837-41.
40. Binder LI, et al. Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta. 2005;1739(2-3):216-23.
41. Horowitz PM, et al. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci. 2004;24(36):7895-902.
42. Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer's disease. Nature. 2017;547(7662):185-90.
43. Zhou Y, et al. Relevance of phosphorylation and truncation of tau to the etiopathogenesis of Alzheimer's disease. Front Aging Neurosci. 2018;10:27.
44. Marciniak E, et al. Tau deletion promotes brain insulin resistance. J Exp Med. 2017;214(8):2257-69.
45. Evans LD, et al. Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways. Cell Rep. 2018;22(13):3612-24.
46. Novak M, Kabat J, Wischik CM. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J. 1993;12(1):365-70.
47. Taniguchi-Watanabe S, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016;131(2):267-80.
48. Lazuardi L, et al. Age-related loss of naive T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology. 2005;114(1):37-43.
49. Vellas B, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res. 2009;6(2):144-51.
50. Henley DB, et al. Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies. Alzheimers Dement. 2012;8(5):407-16.
51. Salloway S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):322-33.